These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39197890)

  • 1. First-line Chemotherapy in Combination With Oral Recombinant Methioninase and a Low-methionine Diet for a Stage IV Inoperable Pancreatic-Cancer Patient Resulted in 40% Tumor Reduction and an 86% CA19-9 Biomarker Decrease.
    Sato M; Han Q; Hozumi C; Kujiraoka H; Mizuta K; Morinaga S; Kang BM; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM
    Anticancer Res; 2024 Sep; 44(9):3885-3889. PubMed ID: 39197890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease.
    Kubota Y; Han Q; Hozumi C; Masaki N; Yamamoto J; Aoki Y; Tsunoda T; Hoffman RM
    Anticancer Res; 2022 May; 42(5):2567-2572. PubMed ID: 35489727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet.
    Sato M; Han Q; Mori R; Mizuta K; Kang BM; Morinaga S; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM
    Anticancer Res; 2024 Apr; 44(4):1499-1504. PubMed ID: 38538002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid Reduction of CEA and Stable Metastasis in an
    Kubota Y; Han Q; Morinaga S; Tsunoda T; Hoffman RM
    In Vivo; 2023; 37(5):2134-2138. PubMed ID: 37652473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extensive Shrinkage and Long-term Stable Disease in a Teenage Female Patient With High-grade Glioma Treated With Temozolomide and Radiation in Combination With Oral Recombinant Methioninase and a Low-methionine Diet.
    Sato M; Han Q; Mizuta K; Mori R; Kang BM; Morinaga S; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM
    In Vivo; 2024; 38(3):1459-1464. PubMed ID: 38688589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
    Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
    JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.
    Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Lwin TM; Higuchi T; Kiyuna T; Miyake M; Oshiro H; Bouvet M; Unno M; Hoffman RM
    Cell Cycle; 2018; 17(7):868-873. PubMed ID: 29623758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel.
    Shibuki T; Otsuka T; Shimokawa M; Nakazawa J; Arima S; Fukahori M; Miwa K; Okabe Y; Koga F; Ueda Y; Kubotsu Y; Makiyama A; Shimokawa H; Takeshita S; Nishikawa K; Komori A; Otsu S; Hosokawa A; Sakai T; Oda H; Kawahira M; Arita S; Honda T; Taguchi H; Tsuneyoshi K; Kawaguchi Y; Fujita T; Sakae T; Nio K; Ide Y; Ureshino N; Shirakawa T; Mizuta T; Mitsugi K
    Sci Rep; 2024 Jul; 14(1):16906. PubMed ID: 39043707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.
    Surinach A; Phung T; Abdul-Rahim O; Khushman M
    Curr Oncol; 2020 Apr; 27(2):e222-e225. PubMed ID: 32489272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
    Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
    BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet.
    Kubota Y; Han Q; Hamada K; Aoki Y; Masaki N; Obara K; Tsunoda T; Hoffman RM
    Anticancer Res; 2022 Aug; 42(8):3857-3861. PubMed ID: 35896248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer.
    Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Kiyuna T; Miyake M; Higuchi T; Oshiro H; Zhang Z; Razmjooei S; Wangsiricharoen S; Bouvet M; Singh SR; Unno M; Hoffman RM
    Cancer Lett; 2018 Sep; 432():251-259. PubMed ID: 29928962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Oral Methioninase (o-rMETase) Combined With Oxaliplatinum Plus 5-Fluorouracil Improves Survival of Mice With Massive Colon-Cancer Peritoneal Carcinomatosis.
    Kim MJ; Han Q; Bouvet M; Hoffman RM; Park JH
    Anticancer Res; 2023 Jan; 43(1):19-24. PubMed ID: 36585181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
    Portal A; Pernot S; Siauve N; Landi B; Lepère C; Colussi O; Rougier P; Zaanan A; Verrière B; Taieb J
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):e23-6. PubMed ID: 24559766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model.
    Yamamoto J; Miyake K; Han Q; Tan Y; Inubushi S; Sugisawa N; Higuchi T; Tashiro Y; Nishino H; Homma Y; Matsuyama R; Chawla SP; Bouvet M; Singh SR; Endo I; Hoffman RM
    Cancer Lett; 2020 Nov; 492():174-184. PubMed ID: 32739322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.
    Meijer LL; Garajová I; Caparello C; Le Large TYS; Frampton AE; Vasile E; Funel N; Kazemier G; Giovannetti E
    Ann Surg; 2020 Jun; 271(6):1137-1147. PubMed ID: 30394883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selecting chemotherapy for pancreatic cancer: Far away or so close?
    Shi S; Yu X
    Semin Oncol; 2019 Feb; 46(1):39-47. PubMed ID: 30611527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis.
    Sasaki T; Kanata R; Yamada I; Matsuyama M; Ozaka M; Sasahira N
    In Vivo; 2019; 33(1):271-276. PubMed ID: 30587635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.